Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines
In combining OVX836 with the NIAID candidates, we intend to unlock the synergy of pairing T- and B-cell activation to drastically improve influenza protection against future pandemic outbreaks.
- In combining OVX836 with the NIAID candidates, we intend to unlock the synergy of pairing T- and B-cell activation to drastically improve influenza protection against future pandemic outbreaks.
- Osivax OVX836 is a nucleoprotein-targeting influenza vaccine developed using the companys proprietary oligoDOM technology.
- Osivax is also exploring the broader application of its technology in both mRNA and subunit vaccines against a variety of indications.
- NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.